UGCG and colorectal cancer: Previous studies wherein GSLs were quantified by mass spectrometry showed that the levels of globo‐series GSLs, particularly Gb3 (or Gb3Cer/CD77), were significantly increased in patients’ colorectal cancers,47, 48 and that inhibition of GCS with Genz‐161 or PDMP significantly decreased the levels of Gb3 and other GSLs in cancer cells, as well as in tissues of animals modeling Gaucher disease.36, 49